Soligenix jumps on positive interim data from late-stage cancer therapy trial

Soligenix

09/07/2024 13:51

** Shares of drug developer Soligenix  SNGX.O  jump 211% to
$6.22 premarket
    ** Co reported positive interim data from late-stage trial
testing its light-based experimental therapy, HyBryte, in
treating patients with early-stage cutaneous T-cell lymphoma
(CTCL)
    ** CTCL is a rare type of cancer that starts in certain
white blood cells and can cause redness or scaly patches on the
skin
    ** HyBryte is a topical ointment applied on lesions and
activated with the help of visible light
    ** SNGX said, to date, six patients have been enrolled and
treated with HyBryte over a time period ranging up to 44 weeks
    ** Co said 3 of 4 patients who have completed at least 12
weeks of therapy achieved "treatment success", when tested on a
scale used to measure the severity of cancerous lesions
    ** As of last close, stock down 83.5% YTD 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))